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ABSTRACT
On 1 February 2013, a marketing authorisation valid 
throughout the European Union was issued for aflibercept 
(Zaltrap) in combination with irinotecan/5-fluorouracil/
folinic acid chemotherapy for the treatment of adults with 
metastatic colorectal cancer resistant to or progressive 
after an oxaliplatin-containing regimen. Aflibercept is a 
recombinant fusion protein which blocks the activation of 
vascular endothelial growth factor (VEGF) receptors and 
the proliferation of endothelial cells, acting as a soluble 
decoy receptor that binds to VEGF-A with higher affinity 
than its native receptors, as well as placental growth 
factor and VEGF-B. The use of aflibercept was studied in 
a randomised, double-blind, placebo-controlled phase III 
study, in patients with metastatic colorectal cancer (mCRC) 
who had previously been treated with an oxaliplatin-
based treatment with or without prior bevacizumab. 
Aflibercept (n=612) was compared with placebo (n=614), 
both in combination with FOLFIRI (infusional fluorouracil, 
leucovorin and irinotecan). The primary endpoint of the 
study was overall survival (OS). The median OS in the 
intent-to-treat population was 13.5 months in subjects 
treated with aflibercept compared with 12.1 months 
for subjects in the control arm (stratified HR=0.817, 
95% CI 0.714 to 0.935, stratified pvalue=0.0032). The 
frequency of adverse events was higher in the aflibercept 
arm compared with the placebo arm, reflecting the 
toxicity profile of anti-VEGF agents in combination with 
chemotherapy. This paper is based on the scientific review 
of the application leading to approval of aflibercept in the 
EU. The detailed scientific assessment report and product 
information for this product are available on the European 
Medicines Agency website (http://www. ema. europa. eu).
Trial registration number NCT00561470, Results.
INTRODUCTION
Colorectal cancer (CRC) is the second-most 
frequently diagnosed cancer, representing 
13.2% and 12.7% of all cancer cases in men 
and women, respectively. CRC was respon-
sible for 215 000 deaths in Europe in 2012. 
At diagnosis, 25% of the patients present 
with metastases and 50% of the patients will 
develop metastases during the course of the 
disease. The 5-year survival rate is approxi-
mately 60%.1
Significant advances in the treatment of 
metastatic colorectal cancer (mCRC) have 
been made due to the introduction of agents 
such as 5-fluorouracil (5FU), leucovorin 
(LV), irinotecan, oxaliplatin and their use at 
different doses and schedule (ie, bolus and 
continuous infusion). Different combina-
tions of these agents have been studied for the 
treatment of mCRC, establishing FOLFOX 
(5-Fluorouracil, Leucovorin and Oxaliplatin) 
and FOLFIRI (infusional fluorouracil, leucov-
orin and irinotecan) as standard of care for 
first-line and second-line treatment of mCRC. 
Patients with mCRC who have received first-
line oxaliplatin-based chemotherapy typically 
receive second-line irinotecan-based chemo-
therapy.2 3
Currently, there are several approved 
targeted therapies used in the treatment of 
mCRC. A benefit was demonstrated in the 
first-line setting with vascular endothelial 
growth factor (VEGF) targeted treatment 
(bevacizumab) combined with irinotecan, 
5FU and LV chemotherapy.4 Bevacizumab 
was also found to be effective in second-line 
treatment when added to FOLFOX4.5 Cetux-
imab and panitumumab are antiepidermal 
growth factor receptor (EGFR) monoclonal 
antibodies which showed benefit in patients 
with mCRC with wild-type KRAS tumours in 
combination with irinotecan-based chemo-
therapy.6–8 The multiple kinase inhibitor 
regorafenib may also be used in patients 
who cannot be treated with fluoropyrim-
idine-based chemotherapy, anti-VEGF or 
anti-EGFR therapies.9
This review focuses on the approval of 
aflibercept (ziv-aflibercept in USA), a recom-
binant human fusion protein acting as a 
high-affinity soluble decoy receptor that 
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can block VEGF activation by preferentially binding to 
VEGF-A, VEGF-B and placental growth factor (PlGF) and 
preventing these factors from activating their endogenous 
receptors.10 Aflibercept was approved for the treatment 
of adults with mCRC that is resistant to or has progressed 
after an oxaliplatin-based regimen. At the time of evalua-
tion, no VEGF-targeted agents had shown clinical benefit 
for this indication in randomised clinical trials.
Non-clinical aspects and clinical pharmacology
Aflibercept is a fusion protein composed of domain 2 of 
vascular endothelial growth factor receptor 1 (VEGFR-1) 
and domain 3 of VEGFR-2 fused to the hinge region of the 
Fc domain of human immunoglobulin G1. The antiangio-
genic effects of aflibercept were studied in vitro where the 
drug inhibited microvessel outgrowth from rat aorta. In 
vivo pharmacology studies indicated that treatment with 
aflibercept inhibited tumour growth of a wide variety of 
mice-implanted tumour cell lines. Aflibercept treatment 
of several established tumours also resulted in a decrease 
in tumour vessel density. The combination of aflibercept 
with 5FU was synergistic in inhibiting the growth of early 
mammary MA13/C tumours. Combining aflibercept with 
irinotecan was also synergistic over several dose levels in 
advanced colon HCT 116 tumours.
In mice, subcutaneous aflibercept administration 
showed activity in gastric and colon adenocarcinoma xeno-
grafts, generally at doses above 2.5 mg/kg. Aflibercept 
formed complexes with endogenous and tumour-derived 
VEGF at active doses. Reductions in microvessel density in 
the liver, pancreatic islets and thyroid follicles were noted 
at all doses.
Pathology findings suggested that the target organs for 
aflibercept toxicity were: bone (interference with growth 
plate maturation, vertebral exostoses), kidney (reversible 
glomerular changes), testis (reversible changes in sperm 
motility and morphology) and ovary (decreased number 
of maturing follicles). Aflibercept was shown to be 
embriotoxic and teratogenic when administered to preg-
nant rabbits during embryogenesis. Female Cynomolgus 
monkeys stopped exhibiting signs of regular menstrual 
bleeding during treatment and this effect did not fully 
resolve during recovery. Decreases in sperm motility and 
increases in the incidence of morphologically abnormal 
spermatozoa were seen in males. The effects seen in males 
were fully reversible within 8–18 weeks of the last dose.
A population pharmacokinetic analysis was conducted 
with aflibercept using data from 1507 patients with 
various malignancies. At the recommended dose regimen 
of 4 mg/kg every 2 weeks, the concentrations of free 
drug were near steady state levels by the second cycle of 
treatment with a volume of distribution of 7.77 L. Being 
a protein, no metabolism studies were conducted with 
aflibercept. Since the drug forms a high molecular weight 
complex by binding to VEGF, it was expected that the 
clearance would be minimal via the renal route. Non-clin-
ical findings suggest that clearance of aflibercept occurs 
via multiple mechanisms, including saturable binding 
to endogenous VEGF as well as proteolytic degradation. 
Weight had an effect on free aflibercept clearance, with 
a 29% increase in exposure in patients weighing ≥100 kg. 
There was limited data available regarding pharmaco-
kinetic changes in patients with severe renal (creatine 
clearance <30 mL/min) or hepatic impairment (total 
bilirubin >3 times of the upper limit of normal and any 
aspartate aminotransferase).
Clinical efficacy
The marketing authorisation application was based on 
the pivotal VELOUR study, which was a randomised, 
double-blind study, comparing the efficacy of afliber-
cept versus placebo in patients treated with FOLFIRI for 
mCRC after failure of an oxaliplatin-based regimen.11 
Eligible patients had inoperable, histologically or cyto-
logically proven adenocarcinoma of the colon or rectum 
and had progressed on or following a first-line oxalipla-
tin-based chemotherapy regimen, or had relapsed within 
6 months of oxaliplatin-based adjuvant chemotherapy 
completion. Patients were excluded if they had received 
prior therapy with irinotecan, within 28 days of prior 
radiotherapy, surgery or chemotherapy or had a history 
of central nervous system metastases. Patients had to have 
adequate bone marrow and serum biochemistry labora-
tory results and no contraindications for anti-VEGF or 
FOLFIRI treatment.
Aflibercept was administered at a dose of 4 mg/kg by a 
1-hour intravenous infusion, every 2 weeks. Placebo was 
administered to the control group using a similar dose 
and schedule. FOLFIRI was administered immediately 
after the aflibercept or placebo infusion using standard 
doses.
A total of 1226 subjects were enrolled in 176 centres in 
28 countries across Europe, North and South America, 
Australia, South Africa and South Korea. Recruited 
patients were stratified according to Eastern Cooperative 
Oncology Group (ECOG) performance status (0 vs 1 vs 
2) and prior bevacizumab treatment (yes or no).
The primary endpoint of the study was overall survival 
(OS). The final survival analysis was performed after a 
median follow-up of 22.3 months and showed a difference 
in median OS of 1.44 months in favour of the afliber-
cept-FOLFIRI arm (13.50 months vs 12.06 months with 
placebo-FOLFIRI), with a stratified HR of 0.817 (95% CI 
0.714 to 0.935), p=0.0032 (figure 1, table 1).
In subgroup analyses, a survival benefit, although less 
pronounced, was also noted in patients who had received 
prior bevacizumab treatment, with a median OS of 12.5 
months in the aflibercept arm versus 11.7 months with 
placebo, HR=0.862 (95% CI 0.676 to 1.100) (table 2).
Secondary endpoints included progression-free survival 
(PFS) and overall response rate (ORR) (by RECIST 
version 1.0). Difference in median PFS was 2.23 months 
in favour of the aflibercept-FOLFIRI arm (median PFS: 
6.9 months vs 4.67 months with placebo-FOLFIRI), with a 
HR of 0.758 (95% CI 0.661 to 0.869), p=0.00007 (table 1). 
In patients evaluable for response rate (1061 subjects), 
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the ORR was also in favour of the aflibercept arm (19.8% 
vs 11.1% in the placebo arm), p=0.0001 (table 1).
Clinical safety
The core safety data originated from the pivotal VELOUR 
study of aflibercept in combination with FOLFIRI for 
oxaliplatin-resistant mCRC. The safety population in the 
aflibercept-FOLFIRI arm included 611 patients (vs 605 
patients in the placebo-FOLFIRI arm).
Patients in the aflibercept arm experienced more treat-
ment-emergent adverse events (AEs) compared with the 
placebo arm (table 3).
Overall, AEs with a notably higher incidence in the 
aflibercept arm included hypertension, dysphonia, 
epistaxis and stomatitis and ulceration (table 4).
Grade 3 or 4 AEs were reported in 62.5% of the 
patients in the placebo arm and 83.5% of the patients 
Figure 1 Kaplan -Meier plot for Overall Survival, VELOUR study. 
Table 1 Main efficacy endpoints, VELOUR study
Efficacy endpoint Placebo-FOLFIRI (n=614) Aflibercept-FOLFIRI (n=612)
OS
  No of death events, n (%) 460 (74.9) 403 (65.8)
  Median OS (months) (95% CI) 12.06 (11.07 to 13.08) 13.50 (12.52 to 14.95)
   Stratified HR (95% CI) 0.817 (0.714 to 0.935)
   Stratified log-rank test p value 0.0032
PFS
  No of events, n (%) 454 (73.9) 393 (64.2)
  Median PFS (months) (95% CI) 4.67 (4.21 to 5.36) 6.90 (6.51 to 7.20)
   Stratified HR (95% CI) 0.758 (0.661 to 0.869)
   Stratified log-rank test p value 0.00007
ORR, CR+PR (%) (95% CI) 11.1 (8.5 to 13.8) 19.8 (16.4 to 23.2)
  Stratified Cochran-Mantel-Haenszel test p value 0.0001
Stratification factors: ECOG performance status (0 vs 1 vs 2), prior bevacizumab (yes vs no).
PFS based on tumour assessment by IRC.
ORR based on tumour assessment by IRC.
CR, complete response; ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; ORR, overall response rate; OS, 
overall survival; PFS, progression-free survival; PR, partial response.
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in the aflibercept arm (table 4). As expected, patients 
on the study drug experienced more anti-VEGF associ-
ated effects, reflecting the pharmacology of aflibercept 
(table 4). There was a trend for more AEs in patients 
over 65 years of age. Certain biological abnormalities 
(decreased blood cell counts, increased alanine amino-
transferase, proteinuria) were reported with a higher 
incidence in the aflibercept arm (table 4).
More deaths due to AEs were recorded in patients 
treated with aflibercept (2.3% vs 0.7% for placebo). The 
most common AEs leading to death not related to disease 
progression were: infection (four deaths), gastrointes-
tinal disorders (three deaths) and respiratory disorders 
(three deaths). Dehydration and hypovolaemia were 
contributing factors for four deaths.
Other important identified risks included posterior 
reversible encephalopathy syndrome, thrombotic micro-
angiopathy, hypersensitivity reactions, wound healing 
complications and increased chemotherapy associated 
toxicity. The risk management plan will address these 
issues as well as potential risks (intravitreal off-label 
use, reproductive and developmental toxicity, cardiac 
dysfunction, osteonecrosis, delayed fracture healing, 
bone exostosis). Missing information concerns the use 
in patients with renal or hepatic impairment, children 
and adolescents, elderly, non-Caucasians, pregnant 
women, fertile men, low performance status (ECOG 
≥2), immune response to aflibercept and long-term 
administration.
Benefit–risk assessment
Based on the results of the pivotal study, aflibercept 
improved OS in patients with oxaliplatin-resistant mCRC. 
However, the difference in median OS in favour of the 
aflibercept arm was modest, of only approximately 1.4 
months. Improvements in PFS and ORR were also noted.
During the evaluation procedure, a major issue for 
discussion was how the modest survival benefit provided 
by aflibercept could be clinically relevant in the current 
treatment landscape, especially in patients pretreated 
Table 2 OS and PFS by prior bevacizumab exposure, VELOUR study
Efficacy endpoint Placebo-FOLFIRI (n=614) Aflibercept-FOLFIRI (n=612)
OS
  Patients with prior bevacizumab, n (%) 187 (30.5) 186 (30.4)
   Median OS (months) (95% CI) 11.7 (9.96 to 13.77) 12.5 (10.78 to 15.47)
   HR (95% CI) 0.862 (0.676 to 1.100)
  Patients with no prior bevacizumab, n (%) 427 (69.5) 426 (69.6)
   Median OS (months) (95% CI) 12.4 (11.17 to 13.54) 13.9 (12.72 to 15.64)
   HR (95% CI) 0.788 (0.671 to 0.925)
PFS
  Patients with prior bevacizumab, n (%) 187 (30.5) 186 (30.4)
   Median PFS (months) (95% CI) 3.9 (3.02 to 4.30) 6.7 (5.75 to 8.21)
   HR (95% CI) 0.661 (0.512 to 0.852)
  Patients with no prior bevacizumab, n (%) 427 (69.5) 426 (69.6)
   Median PFS (months) (95% CI) 5.4 (4.53 to 5.68) 6.9 (6.37 to 7.20)
   HR (95% CI) 0.797 (0.679 to 0.936)
 OS, overall survival; PFS, progression-free survival.





Patients with any TEAE 592 (97.9) 606 (99.2)
Patients with any grades 3–4 TEAE 378 (62.5) 510 (83.5)
Patients with any grades 3–4 related TEAE 284 (46.9) 451 (73.8)
Patients with any serious TEAE 198 (32.7) 294 (48.1)
Patients with any serious related TEAE  93 (15.4) 194 (31.8)
Patients with any TEAE with a fatal outcome*  29 (4.8)  37 (6.1)
Any patient who permanently discontinued due to TEAE  73 (12.1) 164 (26.8)
*The number (%) of events based on the start date of the adverse events includes all TEAEs leading to death whatever the date and cause of 
death.
TEAEs, treatment-emergent adverse events.
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with bevacizumab, since the two drugs have a similar 
mechanism of action.
Pharmacologically, aflibercept was shown to induce 
a broader angiogenesis blockade (VEGF-A, VEGF-B 
and PlGF) compared with bevacizumab (VEGF-A). The 
binding affinity of aflibercept to its receptors was also 
found to be much higher than that of bevacizumab.10 At 
the time of approval, aflibercept was the first antiangio-
genesis agent to show an OS benefit when combined with 
FOLFIRI in a randomised controlled trial (VELOUR). 
ML18147 study was a large open-label trial that investi-
gated the use of continuing bevacizumab treatment in 
case of progression up to 3 months after discontinuing 
first-line bevacizumab plus chemotherapy. Although 
results also showed modest improvements in PFS and 
OS, no direct comparisons with the VELOUR study were 
possible due to differences in trial design as well as the 
small number of patients treated with second-line beva-
cizumab-FOLFIRI in the ML18147 study (64 patients).12
Previous research has shown that angiogenesis 
blockade may be continued beyond initial progression, 
with improvements in OS.12 13 In the aflibercept VELOUR 
study, the improvement in OS noted in patients pretreated 
with bevacizumab was numerically lower compared with 
patients without prior bevacizumab treatment. However, 
the pivotal study was not powered for a formal survival 
comparison between bevacizumab-naive and bevacizum-
ab-treated patients.
The potential to identify angiogenic biomarkers to 
better predict clinical outcomes in mCRC has been 
reviewed in the medical literature.14 15 Taking into 
account the modest survival benefit seen in the study 
population, the EMA requested, as a post-authorisation 
measure, that the applicant conduct a biomarker study 
on plasma and tissue samples available from clinical 
trials, to better define the target population in which the 
benefit–risk balance would be optimal. Hypothesis gener-
ating data was produced initially in the phase II AFFIRM 
study (FOLFOX6 with or without aflibercept in first-line 
treatment of mCRC).16 The programme was expanded 
to include samples from the pivotal VELOUR study and 
another phase III study of aflibercept in Asian patients 
(with a similar design to the VELOUR study). The full 
results of the biomarker programme are expected to be 
submitted in December 2016.
Table 4 AEs, VELOUR study
Placebo-FOLFIRI (n=605) Aflibercept-FOLFIRI (n=611)
AE All grades (%) Grade ≥3(%) All grades (%) Grade ≥3 (%)
  Any 97.9 62.5 99.2 83.5
  Diarrhoea (PT) 56.5  7.8 69.2 19.3
  Asthenic conditions (HLT) 50.2 10.6 60.4 16.9
  Stomatitis and ulceration (HLT) 34.9  5 54.8 13.7
  Infections and infestations (SOC) 32.7  6.9 46.2 12.3
  Hypertension 10.7  1.5 41.4 19.3
  Epistaxis  7.4  0 27.7  0.2
  Weight decreased 14.4  0.8 31.9  2.6
  Dysphonia (PT)  3.3  0 25.4  0.5
  Headache (PT)  8.8  0.3 22.3  1.6
  Dehydration  3  1.3  9  4.3
  Palmar-plantar erythrodysesthesia syndrome  4.3  0.5 11  2.8
Other anti-VEGF-associated AEs
  Arterial thromboembolic event  1.5  0.5  2.6  1.8
  Venous thromboembolic event  7.3  6.3  9.3  7.9
  Fistula formation (GI and non-GI)  0.5  0.2  1.4  0.3
  GI perforation  0.5  0.3  0.5  0.5
  Haemorrhage 19.0  1.7 37.8  2.9
Biological abnormalities
  Neutropaenia 56.3 29.5 67.8 36.7
  Thrombocytopaenia 33.8  1.6 47.4  3.4
  Proteinuria 40.7  1.2 62.2  7.8
  ALT increased 37.1  2.2 47.3  2.7
AEs, adverse events; ALT, alanine aminotransferase; FOLFIRI, infusional fluorouracil, leucovorin and irinotecan; GI, gastrointestinal; HLT, high-
level term; PT, preferred term; SOC, system organ class; VEGF, vascular endothelial growth factor.
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The toxic potential of adding aflibercept to FOLFIRI was 
reflected in the safety data. Compared with the placebo 
arm, there were more treatment discontinuations in the 
aflibercept arm. Grade 3 and 4 AEs were more frequent, 
notably gastrointestinal disorders and infections.
There were more deaths from progressive disease 
in the placebo arm (72.1% vs 60.4% with aflibercept); 
however, more patients in the aflibercept arm died due 
to AEs (2.3% vs 0.7% with placebo). Aflibercept was also 
associated with a range of anti-VEGF class AEs, such as 
hypertension, haemorrhage and non-gastrointestinal 
fistulas.
Patients with severe renal impairment (creatine clear-
ance below 30 mL/min) were not included in the pivotal 
study. Patients with severe liver impairment were also not 
included in the pivotal trial. Given the fact that afliber-
cept would have to be administered in clinical practice 
together with FOLFIRI, the risk of dosing in patients with 
renal and hepatic impairment was judged to be low.
The incidence of grade 3 and 4 AEs was higher in 
patients over 65, which was of concern considering the 
epidemiology of CRC. At the time of approval, it was 
decided to include information in the summary of product 
characteristics about potentially increased risks of AEs 
in the elderly. In order to better characterise the safety 
profile of aflibercept in patients with renal or hepatic 
impairment, as well as the elderly population, the appli-
cant proposed to conduct a post-approval observational 
study to further address the issue of missing information 
in the real-life clinical setting. To address the concern 
related to off-label use of aflibercept, notably regarding 
the contraindication of intravitreal use due to the hyper-
osmotic properties of the formulation, the applicant also 
committed to performing a drug utilisation study.
Based on the totality of evidence provided during the 
assessment procedure, the benefit–risk of aflibercept 
in combination with FOLFIRI for oxaliplatin-resistant 
mCRC was considered positive.
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